Sarepta Therapeutics, Inc. (SRPT) Rating Reiterated by William Blair
William Blair reiterated their outperform rating on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in a report released on Monday morning. William Blair also issued estimates for Sarepta Therapeutics’ Q4 2018 earnings at ($0.39) EPS.
A number of other research firms have also issued reports on SRPT. SunTrust Banks, Inc. restated a buy rating on shares of Sarepta Therapeutics in a research report on Thursday, July 20th. Credit Suisse Group AG set a $64.00 price objective on Sarepta Therapeutics and gave the company a buy rating in a research report on Tuesday, July 18th. Leerink Swann restated a buy rating and set a $60.00 price objective (up previously from $52.00) on shares of Sarepta Therapeutics in a research report on Tuesday, July 18th. BidaskClub upgraded Sarepta Therapeutics from a hold rating to a buy rating in a research report on Friday, June 23rd. Finally, Royal Bank Of Canada restated a buy rating and set a $60.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, June 22nd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have assigned a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $62.79.
Sarepta Therapeutics (SRPT) traded down 0.08% during midday trading on Monday, hitting $50.22. The stock had a trading volume of 622,627 shares. The company’s market cap is $3.23 billion. Sarepta Therapeutics has a 12-month low of $26.26 and a 12-month high of $61.99. The company has a 50-day moving average price of $43.21 and a 200-day moving average price of $36.18.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million during the quarter, compared to analyst estimates of $22.52 million. Sarepta Therapeutics’s revenue was up 350000.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.19) EPS. Equities analysts anticipate that Sarepta Therapeutics will post ($1.22) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Sarepta Therapeutics, Inc. (SRPT) Rating Reiterated by William Blair” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/sarepta-therapeutics-inc-srpt-rating-reiterated-by-william-blair/1612649.html.
In other news, SVP Shamim Ruff sold 11,500 shares of the business’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $50.00, for a total value of $575,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Sandesh Mahatme sold 50,000 shares of the business’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $2,050,000.00. Following the completion of the sale, the chief financial officer now directly owns 41,736 shares in the company, valued at approximately $1,711,176. The disclosure for this sale can be found here. Insiders sold a total of 89,556 shares of company stock worth $3,799,208 in the last three months. Company insiders own 9.60% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of SRPT. Prentiss Smith & Co. Inc. raised its stake in shares of Sarepta Therapeutics by 772.2% in the 2nd quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after buying an additional 3,166 shares in the last quarter. Ameritas Investment Partners Inc. bought a new stake in shares of Sarepta Therapeutics in the 1st quarter worth $127,000. PNC Financial Services Group Inc. raised its stake in shares of Sarepta Therapeutics by 150.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after buying an additional 2,800 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of Sarepta Therapeutics by 116.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after buying an additional 2,474 shares in the last quarter. Finally, Edge Wealth Management LLC bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth $175,000. 65.41% of the stock is currently owned by institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.